Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 May 9;18(5):1017.
doi: 10.3390/ijms18051017.

Exploiting Epigenetic Alterations in Prostate Cancer

Simon J Baumgart  1 , Bernard Haendler  2
Affiliations
Review

Exploiting Epigenetic Alterations in Prostate Cancer

Simon J Baumgart et al. Int J Mol Sci. .

Abstract

Prostate cancer affects an increasing number of men worldwide and is a leading cause of cancer-associated deaths. Beside genetic mutations, many epigenetic alterations including DNA and histone modifications have been identified in clinical prostate tumor samples. They have been linked to aberrant activity of enzymes and reader proteins involved in these epigenetic processes, leading to the search for dedicated inhibitory compounds. In the wake of encouraging anti-tumor efficacy results in preclinical models, epigenetic modulators addressing different targets are now being tested in prostate cancer patients. In addition, the assessment of microRNAs as stratification biomarkers, and early clinical trials evaluating suppressor microRNAs as potential prostate cancer treatment are being discussed.

Keywords: androgen receptor; epigenetics; histone; microRNA; prostate cancer.

PubMed Disclaimer

Conflict of interest statement

The authors are employees and/or own shares of Bayer AG.

Figures

Figure 1
Figure 1
Overview of potential epigenetic targets and selected inhibitors. Straight arrows indicate the addition of acetyl (yellow), methyl (dark green) or phosphoryl (brown) groups to histones, or of a methyl group (purple) to DNA. Removal of these groups is indicated by half-circular black arrows.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Dy G.W., Gore J.L., Forouzanfar M.H., Naghavi M., Fitzmaurice C. Global burden of urologic cancers, 1990–2013. Eur. Urol. 2017;71:437–446. doi: 10.1016/j.eururo.2016.10.008. - DOI - PubMed
    1. Robinson D., Van Allen E.M., Wu Y.M., Schultz N., Lonigro R.J., Mosquera J.M., Montgomery B., Taplin M.E., Pritchard C.C., Attard G., et al. Integrative clinical genomics of advanced prostate cancer. Cell. 2015;161:1215–1228. doi: 10.1016/j.cell.2015.05.001. - DOI - PMC - PubMed
    1. Yap T.A., Smith A.D., Ferraldeschi R., Al-Lazikani B., Workman P., de Bono J.S. Drug discovery in advanced prostate cancer: Translating biology into therapy. Nat. Rev. Drug Discov. 2016;15:699–718. doi: 10.1038/nrd.2016.120. - DOI - PubMed
    1. Attard G., Parker C., Eeles R.A., Schroder F., Tomlins S.A., Tannock I., Drake C.G., de Bono J.S. Prostate cancer. Lancet. 2016;387:70–82. doi: 10.1016/S0140-6736(14)61947-4. - DOI - PubMed
    1. Ciccarese C., Massari F., Iacovelli R., Fiorentino M., Montironi R., di Nunno V., Giunchi F., Brunelli M., Tortora G. Prostate cancer heterogeneity: Discovering novel molecular targets for therapy. Cancer Treat. Rev. 2017;54:68–73. doi: 10.1016/j.ctrv.2017.02.001. - DOI - PubMed

LinkOut - more resources